Search

Displaying results 3671 - 3680 of 9702 in total
  1. Drug

    Efineptakin alfa

    go.drugbank.com/drugs/DB16395
    Investigational

    Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability. … Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response.

    Synonyms: Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc), Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).
  2. Drug

    Efmarodocokin alfa

    go.drugbank.com/drugs/DB16398
    Investigational

    Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  3. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020. … Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.

  4. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  5. Drug

    Tiragolumab

    go.drugbank.com/drugs/DB16409
    Investigational

    Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small

  6. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493].

  7. Drug

    IN01

    go.drugbank.com/drugs/DB16434
    Experimental

    The IN01 Vaccine, sponsored by the Instituto Oncologico Dr Rosell, IN3BIO, and PANGAEA, is a compound containing recombinant bacteria[L30543]. … Of note, the IN01 vaccine is being tested in a Phase I clinical trial in patients with fibrosing interstitial lung disease resulting from SARS-CoV-2 infection (NCT04537130).

  8. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548].

  9. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949).

  10. Drug

    Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)

    go.drugbank.com/drugs/DB16443
    Investigational

    These promising results have secured a Phase I trial (NCT04530656) to evaluate the safety, efficacy, and immunogenicity in healthy Chinese participants. … The Recombinant SARS-CoV-2 Vaccine was created by inserting genes of the SARS-CoV-2 spike protein’s receptor-binding domain into a baculovirus expression system[F4738, A226853].